eCM Journal Scope

eCM Journal (European Cells & Materials) provides a multidisciplinary high-level forum for preclinical biomedical research (Orthopaedics, Cell & tissue engineering, Biomaterials science, and Biomedical engineering). Research fields include, but are not limited to Musculoskeletal, Stem cells, Drug/gene carrier design, Bionanomedicine, and Application of biomaterials. eCM Journal is published by Forum Multimedia Publishing LLC., Part of IMR Press.

• Biomedical materials

Manuscripts must innovate on biomaterials and important biological dimensions, focusing on the various effects of biological materials at the cell, tissue or organism level. In vitro, cytocompatibility studies should use primary cells or more than one cell line and provide more than just simple descriptions of cell viability, spreading, proliferation, mineralisation etc. Major advancements using in vitro, ex vivo or in vivo models as well as relevant opinion papers, are welcome.

Note: Papers focusing only on material or biomechanical properties lacking appropriate consideration of the biological dimension will not be entertained. Manuscripts on the effects of surfaces, coatings, additives etc., in preventing bacterial adhesion must also consider the effect on eukaryotic cells or refer to previously published data using the exact same surfaces.

• Tissue Engineering and Regenerative Medicine (TERM)

Manuscripts concerning the repair or regeneration of connective and mineralized tissues within the body will be considered. Manuscripts focusing on the growth and directed differentiation of stem cells (including but not limited to adult stem cells, tumor stem cells, embryonic stem cells, mesenchymal stem cells, and induced pluripotent stem cells), cell therapy and transplantation, the biological mechanisms underlying stem cell differentiation, and their applications in tissue engineering and medical engineering will also be considered. The paper must mention the effects at the cellular, tissue, or organic level.

Note: TERM papers where only biomechanical testing is utilized without in-depth biological research will not be considered. Orthopaedic or biomedical engineering content lacking cellular or biological aspects will not be considered. Basic physiological and pathological tissue research that are not related to biomedical engineering will not be considered. The use of pooled donor cells (from multiple sources) should be avoided, and if unavoidable, the reasons for their use should be convincingly explained in the manuscript (as well as in the cover letter). Technical specifications and papers that only focus on calculations, materials, or biomechanical models are not accepted.

• Orthopaedics

Manuscripts include studies on diagnosing and treating musculoskeletal conditions such as bone, cartilage, tendon, meniscus, intervertebral disc and ligament injuries. The topic emphasizes innovative approaches in tissue engineering, regenerative medicine, and biomaterials science, aiming to advance the understanding and application of stem cell therapy, gene and drug delivery systems, and bionanomedicine. Manuscripts must provide significant functional biological insights and advancements, ensuring a strong biological dimension in the research presented.

• Musculoskeletal infection

Manuscripts focused on preventing, diagnosing, and treating infections related to body tissues and the musculoskeletal system, as well as significant advancements in in vitro or ex vivo models. This includes, but is not limited to fracture-related infection, peri-prosthetic joint infection, osteomyelitis, septic arthritis, osteosarcoma-related research, etc. Studies on bacteria-host interactions and the basic pathophysiology of infections are welcome, provided the content is related to musculoskeletal infections and other relevant infections.

• Additional Information

Manuscripts focused on developing new biomaterials, drug carriers and bioengineering methods, etc. must provide robust research involving in vitro, ex vivo, or biological mechanisms. Incremental advancements without significant innovation will not be considered by the eCM journal.

Note: The clinical relevance of the work must be briefly mentioned within the abstract and in more detail in the paper. Poor abstracts, which do not concisely cover the papers content will not be sent for review.